Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

NCT07469800 · Recruiting

Last updated 2026-05-28

This clinical trial tests the medication IBI362 in adults who are overweight or obese and have high blood pressure to see how it affects blood pressure compared to a placebo over 16 weeks.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 336 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-04 · est. completion 2027-04

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07469800 ↗

Description as written by the study sponsor.

A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment

Treatments tested

IBI362 Drug

IBI362 will be administered subcutaneously once weekly (QW) in a step-up dose titration regimen over 48 weeks: * Weeks 1-4: 2 mg QW * Weeks 5-8: 4 mg QW * Weeks 9-24: 6 mg QW * Weeks 25-48: 6/9 mg QW.
Placebo Drug

Matching placebo will be administered subcutaneously once weekly (QW) for 48 weeks, with the same number of injections as the IBI362 group to maintain study blinding.

Main thing measured	To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment.
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Overweight, Obesity, Hypertensive
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07469800 ↗